Biohaven Ltd. (NYSE:BHVN) Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its position in Biohaven Ltd. (NYSE:BHVN) by 32.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 405,848 shares of the company’s stock after purchasing an additional 98,779 shares during the period. Pictet Asset Management Holding SA’s holdings in Biohaven were worth $15,158,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Spire Wealth Management purchased a new stake in Biohaven in the 4th quarter valued at $56,000. Amalgamated Bank lifted its holdings in Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after acquiring an additional 527 shares during the period. US Bancorp DE lifted its stake in shares of Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after purchasing an additional 798 shares during the period. KBC Group NV grew its position in Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company’s stock worth $126,000 after buying an additional 1,127 shares during the period. Finally, Diversified Trust Co increased its holdings in Biohaven by 16.6% in the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock valued at $209,000 after buying an additional 795 shares in the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director John W. Childs acquired 32,700 shares of the stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the transaction, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 16.00% of the company’s stock.

Biohaven Trading Down 6.0 %

BHVN stock opened at $22.60 on Wednesday. The company has a market cap of $2.31 billion, a PE ratio of -2.42 and a beta of 1.27. The stock has a 50-day moving average price of $34.55 and a two-hundred day moving average price of $41.21. Biohaven Ltd. has a 12-month low of $21.47 and a 12-month high of $55.72.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). Equities analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the stock a “buy” rating in a research report on Thursday, March 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. Morgan Stanley cut their price target on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Biohaven has a consensus rating of “Buy” and a consensus target price of $62.77.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.